Cardiorenalmetabolic

A study shows mobile integrated health was well received by patients and clinicians despite barriers to broader implementation.

Fix cardiorenalmetabolic care gaps: define ownership, task-shift screening, boost uACR testing, and tackle obesity-driven equity barriers.

A secondary analysis of the HELIOS-B trial found that worse left atrial strain was associated with higher risks of mortality and cardiovascular events.

Frequent adolescent sexual assault and discrimination in employment, housing, and police interactions was associated with higher heart failure risk.

Experts discuss why patients with HFmrEF/HFpEF still receive less urgent, less standardized care than those with reduced ejection fraction.

New hypertension drugs cost over $800,000 per QALY vs generics, well above cost-effectiveness limits, ICER's draft report finds.

Most Medicare beneficiaries with ATTR-CM waited more than 6 months for diagnosis after heart failure onset, with longer delays among women.

Although new guidelines call for universal screening, most Americans with elevated Lp(a) still don't know their number.

All from July, these 5 novel therapeutics each claimed a “first” in their category.

A new AHA scientific statement defines pediatric cardiogenic shock and proposes a 5-stage classification to guide diagnosis, monitoring, and escalation of care.

Researchers found no evidence that cooling beyond 6 hours at 33°C improved neurological outcomes in comatose survivors of out-of-hospital cardiac arrest.

A study of more than 270,000 patients with HF found a U-shaped link between ventricular size and mortality risk.

An FDA committee voted 9-3 that available data did not provide substantial evidence of effectiveness for deramiocel in DMD.

Acoramidis attenuated declines in patient-reported health status through 30 months, complementing previously reported survival and hospitalization benefits.

A target trial emulation found GLP-1 RA initiation was associated with a 21% lower 3-year fragility fracture risk compared with DPP-4 inhibitor therapy.

A new analysis finds up to a 98.8% probability that liberal transfusion lowers 30-day death or myocardial infarction risk vs restrictive care.

Clinicians say workflow changes, not education alone, are closing screening and treatment gaps in cardio-kidney-metabolic (CKM) care.

The autoinjector delivers subcutaneous furosemide with IV-equivalent exposure in under 10 seconds for adults with heart failure or CKD-related edema.

Eplontersen added to standard of care did not significantly reduce cardiovascular death and recurrent events, a study finds.

A digitally enabled quality improvement strategy lowered LDL-C and boosted treatment intensification, though most patients still missed guideline targets.

Left atrial (LA) strain impairment in dilated cardiomyopathy was driven by ventricular dilation, not left bundle branch block.

An analysis found no significant differences in care escalation, readmission, mortality, or guideline-directed therapy use between home-based and inpatient care.

Commercial cardiology prices vary widely by insurer and state, with facility fees for procedures like ICD implantation differing more than 5-fold.

In trials, the first oral PCSK9 inhibitor cut LDL cholesterol by up to 60%, which matched the efficacy of injectable PCSK9 therapies.

Two studies identify molecular targets that could help preserve insulin-producing cell function.